Molecular Templates, Inc.

Pipeline

A Pipeline of Differentiated Oncology Candidates

Engineered toxin bodies (ETBs) are differentiated biologic therapies with unique properties.  Single agent activity and tolerability have been observed with ETB therapy in heavily relapsed/refractory patients.

Program Partner Indication (Target) Preclinical Phase 1 Phase 2 Phase 3 Next Stage
MT-3724 DLBCL monotherapy (CD20)
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
DLBCL combination with GEMOX (CD20)
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
DLBCL combination with Lenalidomide (CD20)
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
MT-5111 Multiple - solid tumors (HER2)
Preclinical Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
Phase 3 Phase not started
TAK-169 Multiple Myeloma (CD38)
Preclinical Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
Phase 3 Phase not started
MT-6402 Multiple - solid tumors (PD-L1)
Preclinical Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
Phase 3 Phase not started
a) Potential for Phase 2 to be pivotal in relapsed/refractory setting as monotherapy
Completed
In-progress
Planning
Phase 2 is potentially pivotal

MT-3724

1st-Generation ETB targeting B-cell Malignancies

MT-3724 has been shown to have monotherapy activity in heavily pre-treated DLBCL patients and was well tolerated in a Phase 1 study. MT-3724 is currently in multiple Phase 2 studies.

View Candidate

MT-5111

2nd-Generation ETB Targeting HER2

MT-5111 is an ETB candidate that has been shown pre-clinically to bind and kill HER2 expressing cells in a way that is consistent with SLTA mediated cellular cytotoxicity. MT-5111 is designed to avoid competition with other HER2 targeted agents and overcome the mechanisms of tumor resistance to current HER2 targeted therapies. MT-5111 is currently in a first-in-human Phase 1 dose-escalation study of patients with HER2+ solid tumors.

View Candidate

TAK-169

2nd-Generation ETB Targeting CD38

TAK-169 is an ETB candidate that has been shown pre-clinically to bind and kill CD38 expressing cells in a way that is consistent with SLTA mediated cellular cytotoxicity. TAK-169 is currently in a first-in-human Phase 1 dose-escalation study of relapsed/refractory myeloma patients.

View Candidate